Merger Arbitrage Tool

Filter by Deal Type:

Note: Premium members can sort this table by Profit, Annualized Profit and Closing Date.

  Symbol Announced Date Acquiring
Company		 Deal
Type		 Clo.
Value		 Clo.
Price		 Last
Price		 Volume Optionable Div. Yield Clo.
Date		 Profit Annu.
Profit
PRVL chart 12/15/2020 Eli Lilly and Company (LLY) Special Conditions $895.39 million $26.50 $23.00 4,563,958 Yes N/A 03/31/2021 15.22% 82.90%
Prevail Therapeutics Inc. merger details:

Expected to close in the first quarter of 2021 for a closing value of $895.39 million. Upon completion of the merger, shareholders of Prevail Therapeutics will receive. $22.50 per share in cash payable at closing plus one non-tradable contingent value right worth up to $4.00 per share in cash , for a total consideration of up to $26.50 per share in cash.

Merger Agreement

Prevail Therapeutics Inc. Investor Relations
Eli Lilly and Company Investor Relations

Prevail Therapeutics Inc. Investor Relations

Eli Lilly and Company Investor Relations

Note: Premium members can sort this table by Symbol, Profit, Annualized Profit and Closing Date. Desktop Version

  Symbol Clo. Date Profit Annu. Profit
PRVL chart 03/31/2021 15.22% 82.90%
Prevail Therapeutics Inc. merger details:

Expected to close in the first quarter of 2021 for a closing value of $895.39 million. Upon completion of the merger, shareholders of Prevail Therapeutics will receive. $22.50 per share in cash payable at closing plus one non-tradable contingent value right worth up to $4.00 per share in cash , for a total consideration of up to $26.50 per share in cash.

Merger Agreement

Prevail Therapeutics Inc. Investor Relations
Eli Lilly and Company Investor Relations

Prevail Therapeutics Inc. Investor Relations

Eli Lilly and Company Investor Relations

Only premium members can access all active mergers and acquisitions. Subscribe today.